Background/Purpose: Increased mortality has been reported in patients treated with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with high minimum inhibitory concentration (MIC) values within the susceptibility range. However, this finding has not been verified in hemodialysis patients, who have much higher invasive MRSA infection rates than nondialysis patients. We aimed at comparing vancomycin MICs between hemodialysis and nondialysis patients, and identifying predictors of high vancomycin MICs and infectionrelated mortality in hemodialysis patients with MRSA bacteremia. Methods: Patients with MRSA bacteremia from January 2008 through December 2009 were enrolled. Vancomycin MIC was determined for each first isolate using the Etest method. Clinical characteristics and vancomycin MICs were compared between hemodialysis and nondialysis patients. Factors associated with high vancomycin MIC (2 mg/mL) and infection-related mortality in hemodialysis patients were analyzed. Results: A total of 162 MRSA bacteremia episodes were identified. Forty-four (27.0%) isolates were obtained from hemodialysis patients and 118 (73.0%) from nondialysis patients. Diabetes (63.3% vs. 39.8%, p Z 0.007) and prior vancomycin exposure in 30 days (31.8% vs. 12.7%, p Z 0.005) were more prevalent in hemodialysis group than in nondialysis group. A higher prevalence of vancomycin MIC of 2 mg/mL was observed in hemodialysis group in comparison with nondialysis group (11.4% vs. 1.7%, p Z 0.016). In following analyses of hemodialysis group, patients with initial presentation of septic shock had a higher risk of vancomycin MIC of 2 mg/ mL than nonseptic shock patients (100.0% vs. 38.5% p Z 0.014). Infection-related mortality was associated with age, Acute Physiology and Chronic Health Evaluation II (APACHE-II) score >15, presence of septic shock, receipt of mechanical ventilation, and failure to remove source of bacteremia in univariate analysis. Conclusion: Hemodialysis patients with MRSA bacteremia are more likely to have a high vancomycin MIC (2 mg/mL) compared with nondialysis patients. Infection-related mortality is associated with the patient's clinical manifestations, including age, APACHE-II score >15, presence of septic shock, receipt of mechanical ventilation, and failure to remove source of bacteremia. Treatment selection should be tailored according to the patient's clinical condition.
Introduction
Staphylococcus aureus is the most common pathogen of bloodstream infections (BSIs) in hemodialysis patients. 1, 2 In 2005, invasive methicillin-resistant S. aureus (MRSA) infections occurred in 45.2/1000 dialysis patients, a rate more than 100 times higher than in nondialysis patients. 3 Patients with MRSA bacteremia who are undergoing hemodialysis have a five-fold higher risk for death and >100% higher hospital costs than uninfected patients undergoing hemodialysis. 4 Vancomycin is one of the most commonly administered antimicrobial agents in hemodialysis patients, because of both high risk of systemic MRSA infections and ease of administration. 5 Despite its sustained in vitro microbiological inhibitory activities, emerging data suggest that vancomycin may be less effective against MRSA infections with minimum inhibitory concentrations (MICs) at the higher end of the susceptibility range. 6 Patients undergoing hemodialysis with MRSA bacteremia had been studied in the United States, 7 but no local data are available in Taiwan. We conducted this study to identify and compare the clinical characteristics and vancomycin MICs between hemodialysis and nondialysis patients with MRSA bacteremia. Factors associated with high vancomycin MIC and infection-related mortality in hemodialysis group were analyzed.
Materials and methods

Study design and patients
This retrospective study was conducted at Tri-Service General Hospital, a 1700-bed primary care and tertiary referral center in northern Taiwan. A list of patients with MRSA bacteremia from January 2008 through December 2009 was retrieved from the hospital's clinical microbiology laboratory database. The patients were divided into two groups. Hemodialysis group comprised all patients who had undergone hemodialysis for more than 3 months prior to enrollment; the remaining patients were classified as nondialysis group. Demographic data, comorbidities, Charlson Comorbidity Index, Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, initial presentation of septic shock, surgery within 30 days, vancomycin exposure within 30 days, receipt of mechanical ventilation, use of vascular access device, vancomycin MICs, and infection-related mortality were retrospectively collected for all patients. Additionally, causes of hemodialysis, source of bacteremia, removal of source of bacteremia, administration of empirical antimicrobial agents, presence of persistent bacteremia, and mortality rate within 14 and 28 days after onset of bacteremia were analyzed in hemodialysis group.
Definition
MRSA bacteremia was defined as the presence of at least one set of blood culture yielding MRSA. Comorbidities were defined as diseases that cause functional impairment and/or predispose patients to infection, such as alcoholism (consumption of >100 g of alcohol per day), chronic obstructive pulmonary disease, dementia, diabetes, heart failure, hematological neoplasms, immunosuppressive therapy (>10 mg of prednisolone daily within 4 weeks, or other agents used as antineoplastic chemotherapy or to prevent organ rejection), liver cirrhosis, solid neoplasms, and valvular heart disease. Causes of hemodialysis were identified by either renal biopsy pathology report or medical record. Septic shock was diagnosed on the basis of standard clinical definition. 8 Hospital-onset BSI was defined as bacteremia occurring >48 hours after hospital admission. Surgery within 30 days was defined as operation under either general or local anesthesia in the past 30 days. All catheters used at onset of bacteremia were recorded. Tunneled catheters were passed under the skin from the insertion site to a separate exit site, where the catheter and its attachments emerge from underneath the skin (Por-A-Cath or double lumen catheter, for instance). Any dose of vancomycin exposure within 30 days was analyzed. Persistent bacteremia was defined as growth of MRSA with identical antibiogram on Day 7 or after, within 30 days of the first positive blood culture. Infection-related mortality was defined as death occurred (1) within 7 days after positive blood cultures or (2) prior to resolution of signs and symptoms of MRSA bacteremia or (3) 7 days after the onset of MRSA bacteremia without any obvious cause other than bacteremia.
Microbiologic methods
Only one MRSA isolate per patient was included in the microbiological portion of this study. All isolates were identified using routine bacteriological procedures. Methicillin susceptibility testing was performed using the disk diffusion method, in accordance with the criteria of the Clinical and Laboratory Standards Institute (CLSI). 9 Vancomycin MIC was determined using the Etest method, according to the manufacturer's guidelines. A suspension of saline calibrated to the 0.5-McFarland turbidity standard was plated onto MuellereHinton agar, onto which Etest strips (AB BIODISK, Solna, Sweden) were applied. The plates were incubated at 35 C for 24 hours. The MIC was interpreted as the zone of inhibition that corresponded to a concentration gradient on the Etest strips, according to the manufacturer's guidelines. Quality control was performed using the CLSI-recommended reference strain (ATCC 29213). 9 
Statistical analysis
Categorical variables were compared using c 2 test or Fisher's exact test, and the Student t test was used for continuous variables. Multivariate logistic regression models were used to assess the predictors of vancomycin MIC of 2 mg/mL and the association with infection-related mortality. All analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
One hundred and sixty-two patients with MRSA bacteremia were included during January 2008 through December 2009, including 44 (27.0%) patients in hemodialysis and 118 (73.0%) patients in nondialysis group (Table 1) . Patients with acute renal failure on temporary hemodialysis, or with end stage renal disease undergoing peritoneal dialysis were not identified in our study. The median age was 69.3 years (range 20e97 years), and 67.2% patients were male. Clinical characteristics of the patients are shown in Table 1 . Diabetes (63.3% vs. 39.8%, p Z 0.007) and prior vancomycin exposure in 30 days (31.8% vs. 12.7%, p Z 0.005) were more prevalent in hemodialysis group than in nondialysis group. Tunneled catheter use was more prevalent in hemodialysis group (31.8% vs. 1.7%, p < 0.001). All MRSA strains were susceptible to vancomycin (MICs !0.5 to 2 mg/mL). The prevalence of vancomycin MICs !1.5 mg/mL was similar in hemodialysis and nondialysis groups in this study (50.0% vs. 48.3%, p Z 0.848). A higher prevalence of vancomycin MIC of 2 mg/mL was observed in hemodialysis group than in nondialysis group (11.4% vs. 1.7%, p Z 0.016).
Infection-related and Day 28 mortality of hemodialysis and nondialysis patients with different vancomycin MICs are illustrated in Fig. 1 . Infection-related mortality ranged between 42.1% and 60.0%, and Day 28 mortality between 40.0% and 50.0% in the two groups. No significant difference in infection-related and Day 28 mortality could be noted between hemodialysis and nondialysis groups regarding different vancomycin MICs.
Factors associated with high vancomycin MIC (2 mg/mL) in hemodialysis patients are analyzed in Table 2 . In univariate analysis, septic shock was associated with a high vancomycin MIC of 2 mg/mL in hemodialysis group (p Z 0.014, Table 2 ). No independent risk factor could be identified in the stepwise logistic regression, with heart failure, APACHE-II score >15, septic shock, and receipt of mechanical ventilation as variables. Other causes of hemodialysis in patients with vancomycin MIC <2 mg/mL included two drug-related nephropathy and four unknown causes. Other causes of MRSA bacteremia included one MRSA pneumonia in patients with a vancomycin MIC of 2 mg/mL, one MRSA pneumonia, and two primary bacteremia in patients with vancomycin MIC <2 mg/mL ( Table 2 ). All hemodialysis patients with S. aureus bacteremia were empirically treated with vancomycin, while pending the antimicrobial susceptibility data. Time of initiation, dosage, and trough level of vancomycin are presented in Tables 2 and 3 .
Infection-related mortality in hemodialysis group in this study was 40.9% (Table 1) . Univariate and multivariate analyses using infection-related mortality as a dependent variable were performed to identify factors associated with infection-related mortality in hemodialysis group (Table 3) . In univariate analysis, age, APACHE-II score >15, presence of septic shock, receipt of mechanical ventilation, and failure to remove source of bacteremia were associated with infection-related mortality. In the stepwise logistic regression, no independent risk factor for infection-related mortality was identified.
Discussion
A higher prevalence of prior vancomycin exposure within 30 days in hemodialysis group than in nondialysis group was observed in this study. Widespread use of glycopeptides, especially vancomycin, 3 is known to be associated with the development of resistant organisms (vancomycin-resistant Enterococcus and S. aureus). 10 Evaluation of the patient's clinical condition and prudent use of vancomycin are important due to the ever-changing bacterial resistance patterns.
A higher prevalence of vancomycin MIC of 2 mg/mL was observed in hemodialysis group in comparison with nondialysis group. Septic shock was associated with high vancomycin MIC (2 mg/mL) in hemodialysis group, although not an independent risk factor in this study. Several studies had been conducted to determine factors predicting high vancomycin MICs in patients with MRSA bacteremia. Patients with a history of prior vancomycin exposure within 30 days or infections in the intensive care unit (ICU) should be considered for high risk of strains with high vancomycin MICs (!1.5 mg/mL).
11 A clinical rule had been developed to predict a vancomycin MIC of 2 mg/mL, which included age >50 years, prior vancomycin exposure, history of MRSA bacteremia, chronic liver disease, and presence of a nontunneled central venous catheter. 12 One caseecontrol study performed in hemodialysis patients with MRSA bacteremia revealed that surgery within previous 6 months and ICU admission were significant risk factors for high vancomycin MIC (2 mg/mL). However, the role of prior vancomycin exposure was not evaluated in the study. 7 We found that age, APACHE-II score >15, presence of septic shock, receipt of mechanical ventilation, and failure to remove source of bacteremia were associated with infection-related mortality in hemodialysis patients with MRSA bacteremia. Prognostic factors associated with mortality in general patients with MRSA bacteremia include complications, acute severe clinical condition at Multivariate analysis was performed with heart failure, APACHE-II score >15, septic shock, and receipt of mechanical ventilation as variables, but failed to draw significance (p > 0.05). APACHE-II Z Acute Physiology and Chronic Health Evaluation II; MIC Z minimum inhibitory concentration; SD Z standard deviation. 14, 15 Li et al 14 suggested that age older than 65 years is independently associated with a higher risk of death in hemodialysis patients with S. aureus bacteremia. MRSA nasal carriers were found to have a 4.99-fold increased risk of infection-related mortality compared with noncarriers in an outpatient hemodialysis population. 15 Failure to treat MRSA bacteremia with vancomycin MICs !1 mg/mL was first addressed by Sakoulas et al. 6 Subsequent studies showed a higher mortality rate in high vancomycin MIC group (MIC 2 mg/mL), 16e20 or treatment failure with vancomycin MICs !1 21 or !1.5 mg/mL. 11 Few studies have focused on the impact of high vancomycin MIC on hemodialysis patients with MRSA bacteremia. In our study, high vancomycin MIC (2 mg/mL) was not associated with infection-related mortality in hemodialysis group. In a caseecontrol study performed among hemodialysis patients with MRSA bacteremia, patients with high vancomycin MIC (2 mg/mL) and low vancomycin MIC ( 0.5 mg/mL) did not differ significantly with regard to mortality in multivariate analysis. 7 According to the Infectious Diseases Society of America guideline for MRSA infections, for isolates with a vancomycin MIC of 2 mg/mL, the patient's clinical response should determine whether the use of vancomycin should be continued or not, independent of vancomycin MICs (A-III). 22 In a literature review by van Hal et al, 23 alternative anti-MRSA agents should be considered for MRSA BSIs with vancomycin MIC !2 mg/mL, as determined by Etest method, especially in patients with persistent disease. 23 There are very little data supporting better survival rates with alternative antibiotics for MRSA BSIs. One retrospective casee control trial showed better outcome with daptomycin than with vancomycin for the treatment of MRSA BSIs with vancomycin MICs of 1.5e2 mg/mL. 24 A study involving 470 MRSA isolates in Taiwan showed that isolates with vancomycin MIC of 2 mg/mL were all susceptible to linezolid and tigecycline, whereas most isolates (98.8%) were susceptible to daptomycin. 25 Future clinical trials for alternative anti-MRSA agents in high vancomycin MIC group are mandatory.
There are some limitations to this study. This study enrolled only patients from a single site. Institutional differences in patient populations, antibiotic prescribing patterns, and resistance patterns may affect its applicability to other institutions. Vancomycin exposure within 30 days may be biased due to retrospective nature of the study and possible missing record in other ambulatory hemodialysis clinics. The possibility of patient-to-patient transmission of high vancomycin MIC strains cannot be excluded due to lack of molecular studies to determine whether one or several clones are driving the observed results. MRSA carriage screening was not performed in our hemodialysis patients. The effect of concomitantly administered antibiotics should be a covariate in future analysis. The failure to identify predictors for high vancomycin MIC (2 mg/mL) and lack of association with infection-related mortality may be of less statistical power due to limited study number. Enrollment of more patients is mandatory in future clinical studies.
In conclusion, a higher prevalence of vancomycin MIC of 2 mg/mL was identified in hemodialysis group than in nondialysis group. More prevalent vancomycin exposure was observed in hemodialysis group. Although not being a significant risk factor for high vancomycin MIC, vancomycin should be used cautiously due to possible development of resistant organisms and potentially predictive of high vancomycin MICs as addressed by other studies. 11, 12 Infection-related mortality is associated with the patient's clinical manifestations, including age, APACHE-II score >15, presence of septic shock, receipt of mechanical ventilation, and failure to remove source of bacteremia. Treatment selection should be tailored according to the patient's clinical condition.
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